1 line
19 KiB
Text
1 line
19 KiB
Text
|
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T17:29:18Z","timestamp":1698514158243},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100018854","name":"Sirtex Medical","doi-asserted-by":"publisher"},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n <jats:title>Objectives<\/jats:title>\n <jats:p>To identify clinical and imaging parameters associated with progression of non-hypervascular hepatobiliary phase hypointense lesions during follow-up in patients who received treatment for hepatocellular carcinoma.<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Methods<\/jats:title>\n <jats:p>A total of 67 patients with 106 lesions were identified after screening 538 patients who underwent gadoxetic acid\u2013enhanced MRI within the SORAMIC trial. All patients were allocated to the trial treatment according to the trial scheme, and 61 of 67 patients received systemic treatment with sorafenib (either alone or combined with locoregional therapies) during the trial period. Follow-up images after treatment according to trial scheme were reviewed for subsequent hypervascularization or > 1 cm size increase. The correlation between progression and several imaging and clinical parameters was assessed using univariable and multivariable analyses.<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Results<\/jats:title>\n <jats:p>On a median 178 (range, 48\u20131072) days follow-up period, progression was encountered in 18 (16.9%) lesions in 12 (17.9%) patients. In univariable analysis size > 12.6 mm (<jats:italic>p<\/jats:italic> = 0.070), ECOG-PS (<jats:italic>p<\/jats:italic> = 0.025), hypointensity at T1-weighted imaging (<jats:italic>p<\/jats:italic> = 0.028), hyperintensity at T2-weighted imaging (<jats:italic>p<\/jats:italic> < 0.001), hyperintensity at DWI images (<jats:italic>p<\/jats:italic> = 0.007), and cirrhosis (<jats:italic>p<\/jats:italic> = 0.065) were correlated with progression during follow-up. Hyperintensity at T2 images (<jats:italic>p<\/jats:italic> = 0.011) was an independent risk factor for progression in multivariable analysis, as well as cirrhosis (<jats:italic>p<\/jats:italic> = 0.033) and ECOG-PS (<jats:italic>p<\/jats:italic> = 0.030).<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Conclusions<\/jats:title>\n <jats:p>Non-hypervascular hepatobiliary phase hypointense lesions are associated with subsequent progression after treatment in patients with HCC. T2 hyperintensity, diffusion restriction, cirrhosis, and higher ECOG-PS could identify lesions with increased risk. These factors should be considered for further diagnostic evaluation or treatment of such lesions.<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Key Points<\/jats:title>\n <jats:p><jats:italic>\u2022 Non-hypervascular hepatobiliary phase hypointense lesions have considerable risk of progression in patients with hepatocellular carcinoma receiving treatment.<\/jats:italic><\/jats:p>\n <jats:p><jats:italic>\u2022 T2 hyperintensity, cirrhosis, ECOG-PS, and hyperintensity at DWI are associated with increased risk of progression.<\/jats:italic><\/jats:p>\n
|